<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11745">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954042</url>
  </required_header>
  <id_info>
    <org_study_id>Pelvital</org_study_id>
    <nct_id>NCT02954042</nct_id>
  </id_info>
  <brief_title>Pelvital Stress Urinary Incontinence Training Device: P-SUIT</brief_title>
  <official_title>Pelvital Stress Urinary Incontinence Training Device: P-SUIT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to compare the clinical benefits of using the Pelvital
      product, in comparison to a sham procedure as a noninvasive treatment for female
      incontinence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 subjects with SUI will be recruited into a randomized, double-blind, sham-controlled
      crossover trial. Subjects will be allocated in a 1:1 ratio (60 per arm) to either the
      control arm (PFMT) or the treatment arm (PFMT in conjunction with the Pelvital therapy).
      Subjects will conduct their respective therapy five minutes a day over the course of six
      weeks. At weeks two, four and six, the subjects will conduct bi-weekly check-ups. After six
      weeks, all patients in the control arm will have the option to cross over into the treatment
      arm if no improvement in symptoms has been shown.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in severity of involuntary urine loss</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Measured by pad testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incontinence episode frequency</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Daily Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Quality of Life questionarie</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Incontinence</condition>
  <arm_group>
    <arm_group_label>Pelvital probe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probe to use for incontinence-Pevital is company name of product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Probe</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo probe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pelvital probe</intervention_name>
    <description>Pelvital probe</description>
    <arm_group_label>Pelvital probe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Probe</intervention_name>
    <description>Placebo Probe</description>
    <arm_group_label>Placebo Probe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. female gender,

          2. between ages 18-70,

          3. clinical assessment by a qualified medical professional and a diagnosis of genuine
             stress urinary incontinence with diverse origin of the condition,

          4. minimum of ten gram increase at initial 24-hour pad weight test

          5. no previous surgeries in the pelvic region,

          6. ability to contract the pelvic floor muscle appropriately after adequate training,

          7. must be able and agree to document incontinence, voiding and fluid intake in a daily
             voiding diary

          8. voluntary participation and signing of the informed consent form

        Exclusion Criteria:

          1. diagnosed mixed or urge urinary incontinence,

          2. previous surgery in the pelvic region,

          3. unable to contract the pelvic floor,

          4. impaired cognitive function

          5. physical limitations that impede the patient's ability to participate (e.g., ability
             to stand or conduct the physical demands of the test protocol),

          6. acute severe infections (e.g., pneumonia),

          7. neurologic conditions (e.g., stroke, epilepsy, Parkinson disease, multiple
             sclerosis),

          8. random blood sugar above 10 mmol/L,

          9. pregnant or actively trying to conceive,

         10. pelvic or gynecological surgery for less than 3 weeks or in the next 8 weeks,

         11. previous treatment biofeedback or similar devices,

         12. history of pelvic irradiation,

         13. concurrent medications with Î±-adrenergic antagonists (e.g., terazosin, tamsulosin,
             doxazosin), diuretics, serotonin-noripinephrine reuptake inhibitors or any other
             medications known to worsen incontinence,

         14. stage III or IV pelvic organ prolapse according to Pelvic Organ Prolapse
             Quantification System,

         15. severe urethral sphincter weakness and/or defect,

         16. suspected urethral and/or vesical fistula,

         17. urinary tract infection or hematuria.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nissrine Nakib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bethany Marlette</last_name>
    <phone>612-626-6661</phone>
    <email>marle025@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Marlette</last_name>
      <phone>612-626-6661</phone>
      <email>marle025@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Nissrine Nakib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>October 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
